Global Phage Therapy Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Phage Therapy Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are one of the most common biological entities that can effectively fight and destroy multi-drug resistant bacteria. When all antibiotics fail to work against an infection, the phages are able to kill the bacteria causing infections, thus helping the medical professionals in saving a life. Bacteriophages are being considered as a new alternative to antibiotics. In this therapy, the viruses are used to inject their genetic material into bacteria and use their host machinery to multiply themselves. This phage therapy is used to treat or to prevent bacterial infections in patients’ body. Bacteriophage therapy also plays a significant role in research fields of molecular biology and biotechnology. These factors enhance the potential scope for drug discovery. Phage has many potential applications in human medicine as well as veterinary science, and agriculture. Phage therapy, viral phage therapy, or phagotherapy is the therapeutic use of bacteriophages for the treatment of pathogenic bacterial infections.

Market Overview:

The latest research study on the global Phage Therapy market finds that the global Phage Therapy market reached a value of USD 176.75 million in 2022. It’s expected that the market will achieve USD 328.99 million by 2028, exhibiting a CAGR of 10.91% during the forecast period.

The market is gradually recovering and there is even an opportunity for growth

With the implementation of epidemic prevention and control measures and the promotion of vaccines, the market order for phage therapy has gradually recovered, the supply chain is also returning to normal, and the operations of related companies are constantly adjusting and recovering. With the occurrence of COVID-19, investment in the field of medicine has been driven, which in turn has driven the development of the phage therapy market. Research papers published on ScienceDirect stated that 8.4% of the total COVID-19 patients are also diagnosed with secondary bacterial infections. They also noticed an inappropriate and excess usage of antibiotics in the COVID treatment which would give rise to antibiotic-resistant organisms. The paper also stated that antibiotic resistance is predicted to be a pandemic by 2050 causing 10 million deaths per year worldwide. This fear, led doctors to go with phase therapy to treat COVID-19 patients. The studies have confirmed that in addition to their antibacterial abilities, phage therapy also displays antiviral properties. Phage therapy also shows effectiveness for building immunity against viral pathogens. The therapy reduces the activation of NF kappa B, thereby producing the antiviral protein phagicin. They also upregulated defensin to induce antiviral immunity.

Presence of alternative treatment for antimicrobial-resistant infections

Majority of bacterial infections can be treated with antibacterial agents and can also be prevented by vaccinations. Moreover, increasing number of drugs are entering into the market for the treatment of antimicrobial-resistant infections. For instance, in August 2019, the U.S. Food and Drug Administration approved Pretomanid Tablets in combination with Bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. Thus, presence of alternative treatment for antimicrobial-resistant infections may hinder the bacteriophage therapy market growth over the forecast period.

Growing understanding of the human microbiome and its role in health and disease

People are establishing links between microbiome composition and diseases ranging from those having obvious bacterial etiology (e.g., infectious and gastrointestinal diseases like bacterial dysentery) to disorders that are not typically associated with bacterial infections, such as obesity, cancer, and others. That means that with bacteriophages people not only have the potential to manage drug-resistant infections, but also a tool that may be able to beneficially modulate the microbiome to address both infectious and noninfectious diseases. The human microbiome comprises hundreds of bacterial species, and maintaining the right balance of “good” and “bad” bacteria in the gut microbiome helps maintain health through multiple mechanisms including modulation of inflammation and regulation of protective gastrointestinal functions. Lytic bacteriophages are superbly suited for gentle and targeted fine-tuning of the microbiome by killing their specific targeted bacterial pathogens without disturbing the normal microflora—a unique biological property that is increasingly explored for developing novel tools for microbiome modulation and research.

Region Overview:

In 2022, the share of the Phage Therapy market in North America stood at 48.17%.

Company Overview:

CJ Cheiljedang is one of the major players operating in the Phage Therapy market, holding a share of 15.84% in 2021.

Segmentation Overview:

As for product types, the DsDNA Bacteriophage segment held the largest market share in 2021.

DsDNA Bacteriophage

The nucleic acid contained in the phage used in this type of phage therapy is double-stranded DNA.

SsDNA Bacteriophage

This type of phage therapy uses SsDNA Bacteriophage, the nucleic acid contained in this type of phage is single-stranded DNA.

SsRNA Bacteriophage

This type of phage therapy uses SsRNA Bacteriophage, and the nucleic acid contained in this type of phage is single-stranded RNA.

Application Overview:

The market's largest segment by application is the segment Animal Health, with a market share of 42.86% in 2022.

Animal Health

Phage therapy can be used in animal health. Phages fight specific bacteria by attaching themselves specifically to them and injecting their genetic material into bacterial cells. With the popularization of large-scale farming, animal diseases spread more and more widely. In order to prevent the huge losses caused by the spread of diseases to farming, bacteriophages can help treat animal diseases. The domestic breeding industry, especially the chicken industry, is often plagued by intestinal diarrhea of livestock and poultry, which is mainly caused by pathogenic microorganisms such as Escherichia coli and Salmonella.

Human Health

Phage therapy can be used to treat human health. Phage therapy may be very important in treating infections that don't respond to antibiotics. For example, it may be used against a powerful Staphylococcus(staph) bacterial infection called MRSA.

Agriculture

Phage therapy can be used in agriculture. Agricultural phages have many benefits. First of all, agricultural phages can stimulate the rhizosphere immunity of crops, and are highly infective to soil-borne diseases, which can achieve precise strikes against soil pathogens and improve crop yields and benefits. It can also reshape the structure of soil flora, restore community diversity, increase the number of beneficial bacteria, and maintain soil health. Secondly, it can also repair the soil, live soil and fertilizer. Improve soil environment, increase ground temperature, improve soil water and fertilizer retention capacity, and reduce environmental pollution caused by excessive use of pesticides.

Food Industry

Phage therapy can be used in the food industry. Treatment with specific phages in the food industry can prevent the decay of products and the spread of bacterial diseases and ultimately promote safe environments in food production, processing, and handling.

Key Companies in the global Phage Therapy market covered in Chapter 3:

NPO Microgen
Cytophage
Locus Biosciences
EasyBio
VetoPhage
Eliava BioPreparations
Intralytix
Phagelux
CJ Cheiljedang
CTC Bio
Proteon Pharmaceuticals
INtODEWORLD
Pherecydes Pharma
MicroMir
Omnilytics
Micreos

In Chapter 4 and Chapter 14.2, on the basis of types, the Phage Therapy market from 2018 to 2029 is primarily split into:

DsDNA Bacteriophage
SsDNA Bacteriophage
SsRNA Bacteriophage
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Phage Therapy market from 2018 to 2029 covers:

Animal Health
Human Health
Agriculture
Food Industry
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)